视网膜脱离

辅助性玻璃体内药物治疗

该辅助治疗的主要目标是降低术后发生增生性玻璃体视网膜病变的风险。尚无有效药物。[44]Charteris DG, Aylward GW, Wong D, et al; PVR Study Group. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. 2004;111:2240-2245.http://www.ncbi.nlm.nih.gov/pubmed/15582080?tool=bestpractice.com[45]Kirchhof B. Strategies to influence PVR development. Graefes Arch Clin Exp Ophthalmol. 2004;242:699-703.http://www.ncbi.nlm.nih.gov/pubmed/15309556?tool=bestpractice.com[46]Wickham L, Bunce C, Wong D, et al. Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 2007;114:698-704.http://www.ncbi.nlm.nih.gov/pubmed/17398320?tool=bestpractice.com